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Summary
The key messages in 20 points
1. Blood pressure, epidemiology and risk. Glob-
ally, over 1 billion people have hypertension. As
populations age and adopt more sedentary lifestyles,
the worldwide prevalence of hypertension will con-
tinue to rise towards 1.5 billion by 2025. Elevated
blood pressure (BP) is the leading global contributor
to premature death, accounting for almost 10 million
deaths in 2015, 4.9 million due to ischaemic heart
disease and 3.5million due to stroke. Hypertension is
also a major risk factor for heart failure, atrial fibrilla-
tion, chronic kidney disease (CKD), peripheral artery
disease (PAD) and cognitive decline.
2. Definition of hypertension. The classification of
BP and the definition of hypertension is unchanged
from previous European guidelines, and is defined
as an office SBP at least 140mmHg and/or DBP at
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least 90mmHg, which is equivalent to a 24-h ABPM
average of at least 130/80mmHg, or a home blood
pressure monitoring (HBPM) average at least 135/
85mmHg.
3. Screening and diagnosis of hypertension.
Hypertension is usually asymptomatic (hence the
term ‘silent killer’). Because of its high prevalence,
screening programmes should be established to
ensure that BP is measured in all adults, at least
every 5 years and more frequently in people with a
high-normal BP. When hypertension is suspected
because of an elevated screening BP, the diagnosis
of hypertension should be confirmed either by
repeated office BP measurements, over a number
of visits, or by out-of-office BP measurement using
24-h ABPM or by HBPM.
4. The importance of cardiovascular risk assess-
ment and detection of HMOD. Other cardiovas-
cular risk factors such as dyslipidaemia and
metabolic syndrome frequently cluster with hyper-
tension. Thus, unless the patient is already at high or
very high risk due to established CVD, formal car-
diovascular risk assessment is recommended using
the SCORE system. It is important to recognize,
however, that the presence of HMOD, especially
left ventricular hypertrophy (LVH), chronic kidney
disease (CKD) or advanced retinopathy, further
increases the risk of cardiovascular morbidity and
mortality, and should be screened for as part of risk
assessment in hypertensive patients because the
SCORE system alone may underestimate their risk.
5. Think – could this patient have secondary
hypertension? For most people with hyperten-
sion, no underlying cause will be detected. Second-
ary (and potentially remediable) causes of
hypertension are more likely to be present in people
with young onset of hypertension (< 40 years),
people with severe or treatment-resistant hyperten-
sion, or people who suddenly develop significant
hypertension in midlife on a background of previ-
ously normal BP. Such patients should be referred
for specialist evaluation.
6. Treatment of hypertension – importance of
lifestyle interventions. The treatment of hyper-
tension involves lifestyle interventions and drug
therapy. Many patients with hypertension will
require drug therapy, but lifestyle interventions
are important because they can delay the need for
drug treatment or complement the BP-lowering
effect of drug treatment. Moreover, lifestyle inter-
ventions such as sodium restriction, alcohol moder-
ation, healthy eating, regular exercise, weight
control and smoking cessation, all have health ben-
efits beyond their impact on BP.
7. When to consider drug treatment of hyperten-
sion. The treatment thresholds for hypertension are
now less conservative than they were in previous
guidelines. We now recommend that patients with
lowmoderate risk grade 1 hypertension (office BP
140–159/90–99mmHg), even if they do not have
HMOD, should now receive drug treatment if their
BP is not controlled after a period of lifestyle inter-
vention alone. For higher risk patients with grade
1hypertension, including those with HMOD, or
patients with higher grades of hypertension (e.g.
grade 2 hypertension,160/100mmHg), we recom-
mend initiating drug treatment alongside lifestyle
interventions. These recommendations apply to all
adults up to the age of 80 years.
8. Special considerations in frail and older
patients. It is increasingly recognized that biologi-
cal rather than chronological age, as well as con-
sideration of frailty and independence, are
important determinants of the tolerability of and
likely benefit from BP-lowering medications. It is
important to note that even in the very old (i.e. > 80
years), BP-lowering therapy reduces mortality,
stroke and heart failure. Thus, these patients should
not be denied treatment, or have treatment with-
drawn simply on the basis of age. For people more
than 80 years of age who have not yet received
treatment for their BP, treatment is recommended
when their office SBP is at least 160mmHg, provided
that the treatment is well tolerated.
9. How low should SBP be lowered? This has been a
hotly debated topic. A key discussion point is the
balance of potential benefits versus potential harm
or adverse effects. This is especially important
whenever BP targets are lowered, as there is a
greater potential for harm to exceed benefit. Thus,
in this guideline, we recommend a target range. The
evidence strongly suggests that lowering office SBP
to less than 140mmHg is beneficial for all patient
groups, including independent older patients. There
is also evidence to support targeting SBP to
130mmHg for most patients, if tolerated. Even lower
SBP levels (<130mmHg) will be tolerated and
potentially beneficial for some patients, especially
to further reduce the risk of stroke. SBP should not
be targeted to below 120mmHg because the bal-
ance of benefit versus harm becomes concerning at
these levels of treated SBP.
10. Blood pressure targets in old and very old
patient. As discussed above, independence, frailty
and comorbidities will all influence treatment deci-
sions, especially in older ( 65 years) and very old
(> 80 years) patients. The desired SBP target range
for all patients aged more than 65 years is less than
140mmHg but not less than 130mmHg. This is
lower than in previous guidelines and may not be
achievable in all older patients, but any BP lowering
towards this target is likely to be beneficial provided
that the treatment is well tolerated.
11. Blood pressure targets in patients with diabe-
tes and/or chronic kidney disease. The BP-treat-
ment targets for patients with diabetes or kidney
disease have been a moving target in previous
guidelines because of seemingly contradictory
results frommajor outcome trials andmeta-analyses.
For diabetes, targeting the SBP to less than
140mmHg and towards 130mmHg, as recom-
mended for all other patient groups, is beneficial
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on major outcomes. Moreover, targeting SBP to less
than 130mmHg, for those who will tolerate it, may
further reduce the risk of stroke but not other major
outcomes. SBP should not be lowered below
120mmHg. For patients with CKD, the evidence
suggests that the target BP range should be less
than 140mmHg but not less than 130mmHg.
12. How low should DBP be lowered? The optimal
DBP target has been less well defined, but a DBP
target of less than 80mmHg is recommended. Some
patients with stiff arteries and isolated systolic
hypertension will already have DBP levels below
this target. These are high-risk patients and the low
DBP should not discourage treatment of their ele-
vated SBP to the recommended target, provided that
treatment is well tolerated.
13. The need to do better on blood pressure con-
trol. A key message in this guideline is the need to
do better at improving BP control rates. Despite the
overwhelming evidence of treatment benefit, on
average, less than 50% of patients with treated
hypertension achieve a SBP target of less than
140mmHg. Physician inertia (inadequate up-titra-
tion of treatment, especially frommonotherapy) and
poor patient adherence to treatment (especially
when based on multiple pills) are now recognized
as the major factors contributing to poor BP control.
14. Start treatment in most patients with two
drugs, not one.Monotherapy is usually inadequate
therapy for most people with hypertension; this will
be especially true now that the BP-treatment targets
for many patients are lower than in previous guide-
lines. This guideline sets out to normalize the con-
cept that initial therapy for the majority of patients
with hypertension should be with a combination of
two drugs, not a single drug. The only exception
would be in a limited number of patients with a
lower baseline BP close to their recommended
target, who might achieve that target with a single
drug, or in some frailer old or very old patients, in
whom more gentle reduction of BP may be desir-
able. Evidence suggests that this approach will
improve the speed, efficiency and consistency of
initial BP lowering and BP control, and is well
tolerated by patients.
15. A single pill strategy to treat hypertension.
Poor adherence to longer-term BP lowering medi-
cation is now recognized as a major factor contrib-
uting to poor BP control rates. Research has shown a
direct correlation between the number of BP-low-
ering pills and poor adherence to medications.
Moreover, SPC therapy has been shown to improve
adherence to treatment. SPC therapy is now the
preferred strategy for initial two-drug combination
treatment of hypertension and for three-drug com-
bination therapy when required. This will control
the BP in most patients with a single pill and could
transform BP control rates.
16. A simplified drug-treatment algorithm. We
have simplified the treatment strategy so that
patients with uncomplicated hypertension and
many patients with a variety of comorbidities (e.g.
HMOD, diabetes, PAD or cerebrovascular disease)
receive similar medication. We recommend a com-
bination of an angiotensin-converting enzyme
(ACE) inhibitor or angiotensin receptor blocker
(ARB) with a CCB or thiazide/thiazide-like diuretic
as initial therapy for most patients. For those requir-
ing three drugs, we recommend a combination of an
ACE inhibitor or ARB with a CCB and a thiazide/
thiazide-like diuretic. We recommend beta-blockers
be used when there is a specific indication for their
use (e.g. angina, postmyocardial infarction, HFrEF
or when heart-rate control is required).
17. Hypertension in women and in pregnancy. In
women with hypertension who are planning preg-
nancy, ACE inhibitors or ARBs and diuretics should
be avoided and the preferred medications to lower
BP, if required, include alpha-methyl dopa, labetalol
or CCBs. The samedrugs are suitable if BP lowering is
required in pregnant women. ACE inhibitors or ARBs
should not be used be used in pregnant women.
18. Is there a role for device-based therapy for the
treatment of hypertension? A number of device-
based interventions have been developed and stud-
ied for the treatment of hypertension. To date, the
results from these studieshavenotprovided sufficient
evidence to recommend their routine use. Conse-
quently, the use of device-based therapies is not
recommended for the treatment of hypertension,
unless in the context of clinical studies and random-
ized controlled trials, until further evidence regarding
their safety and efficacy becomes available.
19. Managing cardiovascular disease risk in hyper-
tensive patients, beyond BPS statins. For hyper-
tensive patients at moderate CVD risk or higher, or
those with established CVD, BP lowering alone will
not optimally reduce their risk. These patients
would also benefit from statin therapy, which fur-
ther reduces the risk of a myocardial infarction by
approximately one-third and stroke by approxi-
mately one-quarter, even when BP is controlled.
Similar benefits have been seen in hypertensive
patients at the border between low and moderate
risk. Thus, many more hypertensive patients would
benefit from statin therapy than are currently receiv-
ing this treatment.
20. Managing cardiovascular disease risk in hyper-
tensive patients, beyond BP – antiplatelet ther-
apy. Antiplatelet therapy, especially low-dose
aspirin, is recommended for secondary prevention
in hypertensive patients, but is not recommended for
primary prevention (i.e. in patients without CVD).
INTRODUCTION
These 2018 European Society of Cardiology/European
Society of Hypertension (ESC/ESH) guidelines for the man-
agement of arterial hypertension are designed for adults
with hypertension, that is aged at least 18 years. The
purpose of the review and update of these guidelines
was to evaluate and incorporate new evidence into the
Williams et al.
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guideline recommendations. The specific aims of these
guidelines were to produce pragmatic recommendations
to improve the detection and treatment of hypertension,
and to improve the poor rates of BP control by promoting
simple and effective treatment strategies.
Principles
These fundamental principles are to base recommendations
on properly conducted studies, identified from an extensive
review of the literature; to give the highest priority to data
from randomized controlled trials (RCTs); and to also con-
sider well conducted meta-analyses of RCTs as strong evi-
dence. This contrastswith networkmeta-analyses,whichwe
do not consider to have the same level of evidence because
many of the comparisons are nonrandomized; to recognize
that RCTs cannot address many important questions related
to the diagnosis, risk stratification and treatment of hyper-
tension,whichcanbeaddressedbyobservational or registry-
based studies of appropriate scientific calibre; to grade the
level of scientific evidence and the strength of recommen-
dations according to ESC recommendations; to recognize
that opinionsmaydiffer onkey recommendations,which are
resolved by voting; and to recognize that there are circum-
stances in which there is inadequate or no evidence, but the
question is important for clinical practice and cannot be
ignored. In these circumstances, we resort to pragmatic
expert opinion and endeavour to explain its rationale.
What is new and what is changed in the 2018
European Society of Cardiology/European
Society of Hypertension hypertension
guidelines?
Because of new evidence on several diagnostic and therapeu-
tic aspects of hypertension, the present guidelines differ from
the 2013 ones in several points indicated as follows (Fig. 1).
New concepts
Blood pressure measurement
1. Wider use of out-of-office BPmeasurementwith ABPM
and/or HBPM, especially HBPM, as an option to con-
firm the diagnosis of hypertension, detect white coat
and masked hypertension and monitor BP control.
Less conservative treatment of blood pressure in
older and very old patients
1. Lower BP thresholds and treatment targets for older
patients, with an emphasis on considerations of bio-
logical rather than chronological age (i.e. the impor-
tance of frailty, independence and the tolerability of
treatment).
2. Recommendation that treatment should never be
denied or withdrawn on the basis of age, provided
that treatment is tolerated.
A SPC treatment strategy to improve blood pressure
control
1. Preferred use of two-drug combination therapy for the
initial treatment of most people with hypertension.
2. A single-pill treatment strategy for hypertension with
the preferred use SPC therapy for most patients.
3. Simplified drug-treatment algorithms with the pre-
ferred use of an ACE inhibitor or ARB combined with
a CCB or/and a thiazide/thiazide-like diuretic as the
core treatment strategy for most patients, with beta-
blockers used for specific indications.
New target ranges forbloodpressure in treatedpatients
1. Target BP ranges for treated patients to better identify
the recommended BP target and lower safety bound-
aries for treated BP, according to a patient’s age and
specific comorbidities.
Detecting poor adherence to drug therapy
1. A strong emphasis on the importance of evaluating
treatment adherence as a major cause of poor
BP control.
A key role for nurses, pharmacists in the longer-term
management of hypertension
1. The important role of nurses and pharmacists in the
education, support and follow-up of
2. Treated hypertensive patients are emphasized as part
of the overall strategy to improve BP control.
DEFINITIONS AND CLASSIFICATIONS
The relationship between BP and cardiovascular and renal
events is continuous, making the distinction between nor-
motension and hypertensionbased on cut-off BP val-
uessomewhat arbitrary. ‘Hypertension’ is defined as the
level of BP at which the benefits of treatment (either with
lifestyle interventions or drugs), unequivocally outweigh
the risks of treatment, as documented by clinical trials. This
evidence has been reviewed and provides the basis for the
recommendation that the classification of BP and definition
of hypertension remain unchanged from previous ESH/ESC
guidelines (Fig. 2).
DIAGNOSTIC EVALUATION
Evaluation of the cardiovascular risk
Quantification of total cardiovascular risk (i.e. the likelihood
of a person developing a cardiovascular event over a defined
period) is an important part of the risk-stratification process
for patients with hypertension. Many cardiovascular risk-
assessment systems are available and most project 10-year
risk. Since 2003, the Europeanguidelines onCVDprevention
have recommended use of the Systematic COronary Risk
Evaluation (SCORE) system (Figs. 3–5) because it is basedon
large, representative European cohort datasets (http://
www.escardio.org/Guidelines-&-Education/Practice-tools/
CVD-prevention-toolbox/SCORE-Risk-Charts). The SCORE
system only estimates the risk of fatal cardiovascular events.
Measurement of blood pressure
Auscultatory or oscillometric semiautomatic or automatic
sphygmomanometers are the preferred method for
2018 Practice Guidelines for the management of hypertension
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measuring BP in the doctor’s office. These devices should
be validated according to standardized conditions and
protocols.
BP can be highly variable, thus the diagnosis of hyper-
tension should not be based on a single set of BP readings at
a single office visit, unless the BP is substantially increased
(e.g. grade 3 hypertension) and there is clear evidence of
HMOD (e.g. hypertensive retinopathy with exudates and
haemorrhages, or LVH, or vascular or renal damage). For all
others (i.e. almost all patients), repeat BP measurements at
FIGURE 1 Changes in ESC/ESH recommendations between 2013 and 2018. The codes used for the classes of recommendations and level of evidence are found in
supplementary Figure 1, http://links.lww.com/HJH/B29.
Williams et al.
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repeat office visits have been a long-standing strategy to
confirm a persistent elevation in BP, as well as for the
classification of the hypertension status in clinical practice
and RCTs.
White-coat hypertension refers to the untreated condi-
tion in which BP is elevated in the office, but is normal
when measured by ABPM, HBPM, or both. Conversely,
‘masked hypertension’ refers to untreated patients in whom
the BP is normal in the office, but is elevated when mea-
sured by HBPM or ABPM. The term ‘true normotension’ is
used when both office and out-of-office BP measurements
are normal, and ‘sustained hypertension’ is used when both
are abnormal. In white-coat hypertension, the difference
between the higher office and the lower out-of-office BP is
referred to as the ‘white-coat effect’ and is believed to
mainly reflect the pressor response to an alerting reaction
elicited by office BP measurements by a doctor or a nurse,
although other factors are probably also involved (Fig. 6).
These guidelines also support the use of out-of-office BP
(i.e. HBPM and/or ABPM) (Figs. 7–10) as an alternative
strategy to repeated office BPmeasurements, to confirm the
diagnosis of hypertension, when these measurements are
FIGURE 1 (Continued).
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logistically and economically feasible. This approach can
provide important supplementary clinical information, for
example detecting white-coat hypertension, which should
be suspected, especially in people with grade 1 hyperten-
sion on office BP measurement and in whom there is no
evidence of HMOD or CVD. A particular challenge is
the detection of masked hypertension. Masked hyperten-
sion is more likely in people with a BP in the high-normal
range in whom out-of-office BP should be considered to
exclude masked hypertension. Out-of-office BP measure-
ments are also indicated in other specific circumstances
(Figs. 7–9).
All adults should have their BP recorded in their medical
record and be aware of their BP, and further screening
should be undertaken at regular intervals with the fre-
quency dependent on the BP level as illustrated in Fig. 10.
FIGURE 1 (Continued).
Williams et al.
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Clinical evaluation
The information to be obtained at the time of the first
diagnosis of hypertension is indicated in Figs. 11–14.
TREATMENTOF HYPERTENSION
The routine treatment of hypertension involves lifestyle
interventions for all patients (including those with high
normal BP) and drug therapy for most patients.
All guidelines agree that patients with grade 2 or 3
hypertension should receive antihypertensive drug treat-
ment alongside lifestyle interventions. Guidelines are also
consistent in recommending that patients with grade 1
hypertension and high cardiovascular risk or HMOD should
be treated with BP-lowering drugs. There has been less
consistency about whether BP-lowering drugs should be
offered to patients with grade 1 hypertension and low-to-
moderate cardiovascular risk or grade 1 hypertension in
older patients (> 60 years), or the need for BP-lowering
drug treatment in patients with high-normal BP levels.
This uncertainty relates to the fact that low-risk patients
with high-normal BP or grade 1 hypertension have
rarely been included in RCTs, and that in older patients,
RCTs have invariably recruited patients with at least
grade 2 hypertension.
Drug treatment strategy and blood pressure
targets (Figs 15–20)
The level to which BP should be lowered with drug
treatment will depend on the patients’ age, comorbidities
and tolerability of treatment. Corresponding BP targets for
home and ambulatory BP are less well established, but an
office BP less than 130mmHg probably corresponds to a
FIGURE 2 Classification of office blood pressure and definitions of hypertension grades.
FIGURE 3 Evaluation of the cardiovascular risk: 10-year cardiovascular risk categories SCORE. CKD, chronic kidney disease; CVD cardiovascular disease; eGFR, estimated
glomerular filtratiom rate; LVH, left ventricular hypertrophy; PAD, peripheral artery disease; TIA, transient ischaemic attack.
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FIGURE 4 Risk modifiers increasing cardiovascular risk estimated by the SCORE system. CKD, chronic kidney disease; CVD cardiovascular disease.
FIGURE 5 Classification of hypertension stages according to blood pressure levels, presence of risk factors, hypertension-mediated organ damage or comorbidities.
FIGURE 6 Office blood pressure measurements. AF, atrial fibrillation.
Williams et al.
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FIGURE 7 Definitions of hypertension according to office, ambulatory and home blood pressure levels.
FIGURE 9 Clinical indications for home blood pressure monitoring (HBPM) or ambulatory blood pressure monitoring (ABPM). CKD, chronic kidney disease; HMOD,
hypertension-mediated organ damage.
FIGURE 8 Advantages and disadvantages of ambulatory blood pressure monitoring and home blood pressure monitoring.
2018 Practice Guidelines for the management of hypertension
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FIGURE 10 Screening for hypertension.
FIGURE 11 Key information to be collected in personal and family medical history (1). AF, atrial fibrilation; CKD, chronic kidney disease; CVD cardiovascular disease;
HMOD, hypertension-mediated organ damage; TIA, transient ischaemic attack.
FIGURE 12 Key information to be collected in personal and family medical history (2).
Williams et al.
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FIGURE 13 Routine work-up for evaluation of hypertensive patients.
FIGURE 14 Assessments of hypertension-mediated organ damage (HMOD).
2018 Practice Guidelines for the management of hypertension
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24-h ABPM SBP of less than 125mmHg and a home average
SBP of less than 130mmHg.
The core algorithm is also appropriate for most patients
with HMOD, cerebrovascular disease, diabetes or periph-
eral artery disease.
Drug treatment strategy for specific clinical
situations: coronary heart disease, chronic
kidney disease, heart failure, atrial fibrillation
(Figures 21–25)
Device-based therapy for hypertension
The actual recommendation is the following: ‘Use of
device-based therapies is not recommended for the routine
treatment of hypertension, unless in the context of clinical
studies and RCTs, until further evidence regarding their
safety and efficacy becomes available’.
Resistant hypertension
Hypertension is defined as resistant to treatment when the
recommended treatment strategy fails to lower office SBP
and DBP values to below 140 and/or 90mmHg, respec-
tively, and the inadequate control of BP is confirmed by
ABPM or HBPM, in patients whose adherence to therapy
has been confirmed (Figs. 26 and 27). The recommended
treatment strategy should include appropriate lifestyle mea-
sures and treatment with optimal or best-tolerated doses of
three or more drugs that should include a diuretic and
typically an ACE inhibitor or ARB, and a CCB.
FIGURE 15 Initiation of blood pressure-lowering treatment (lifestyle changes and medication at different initial office BP levels). CAD, coronary artery disease; CVD,
cardiovascular disease; HMOD, hypertension-mediated organ damage.
FIGURE 16 Summary of office blood pressure thresholds for treatment.
Williams et al.
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FIGURE 17 Office blood pressure treatment targets in hypertensive: recommendations. CVD, cardiovascular disease.
FIGURE 18 Lifestyle changes. WC, waist circumference.
2018 Practice Guidelines for the management of hypertension
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FIGURE 19 Core drug-treatment strategy for uncomplicated hypertension. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB,
calcium channel blockers.
FIGURE 20 Compelling and possible contraindications to the use of specific antihypertensive drugs. ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor
blockers; LV EF, left ventricular ejecttion fraction.
FIGURE 21 Drug-treatment strategy for hypertension and coronary artery disease. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CCB, calcium channel blockers; CVD, cardiovascular disease.
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FIGURE 22 Drug-treatment strategy for chronic kidney disease. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers;
CVD, cardiovascular disease. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; CKD, chronic kidney disease.
FIGURE 23 Drug-treatment strategy for hypertension and heart failure with reduced ejection fraction. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin
receptor blockers.
FIGURE 24 Drug-treatment strategy for hypertension and atrial fibrillation. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers;
CCB, calcium channel blockers; DHP, dihydropyridine.
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Secondary hypertension
Secondary hypertension is hypertension due to an identifi-
able cause, which may be treatable with an intervention
specific to the cause (Figs. 28–31). A high index of suspi-
cion and early detection of secondary hypertension is
important because interventions may be curative, espe-
cially in younger patients.
Hypertension emergency
Hypertension emergencies are situations in which severe
hypertension (grade 3) is associated with acute HMOD,
which is often life-threatening and requires immediate but
careful intervention to lower BP, usually with intravenous
(i.v.) therapy (Figs. 32 and 33). The rate and magnitude of
increase in BP may be at least as important as the absolute
level of BP in determining the magnitude of organ injury.
Treatment recommendations in special
situations (Figs. 34–42)
FOLLOW-UP OF PATIENTS
Frequency of visits
After the initiation of antihypertensive drug therapy, it is
important to review the patient at least once within the first 2
months to evaluate the effects on BP and assess possible side
effects until BP is under control. The frequency of reviewwill
FIGURE 25 Treatment targets in special conditions.
FIGURE 26 Resistant hypertension characteristics, secondary causes and contributing factors. CKD, chronic kidney disease; HMOD, hypertension-mediated organ damage;
LVH, left ventricular hypertension.
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FIGURE 27 Resistant hypertension: recommendations. ABPM, ambulatory blood pressure monitoring; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor
blockers; CCB, calcium channel blockers; HBPM, home blood pressure monitoring.
FIGURE 28 Patients characteristics that should raise the suspicion of secondary hypertension. CKD, chronic kidney disease; HMOD, hypertension-mediated organ damage.
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depend on the severity of hypertension, the urgency to
achieve BP control and the patient’s comorbidities.
Patients with high-normal BP or white-coat hypertension
frequently have additional risk factors, including HMOD,
and have a higher risk of developing sustained hyperten-
sion. Thus, even when untreated, they should be scheduled
for regular follow-up (at least annual visits) to measure
office and out-of-office BP, as well as to check the cardio-
vascular risk profile.
Adherence to therapy (Fig. 43)
There is growing evidence that poor adherence to treat-
mentin addition to physician inertia (i.e. lack of thera-
peutic action when the patient’s BP is uncontrolled)is the
most important cause of poor BP control. Nonadherence to
antihypertensive therapy correlates with higher risk of
cardiovascular events.
Note: The levels of evidence for each of the recommen-
dations presented in the figures can be found in the original
FIGURE 29 Common causes of secondary hypertension (1). CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; PAD, peripheral artery disease.
FIGURE 30 Common causes of secondary hypertension (2). ABI, ankle–brachial index.
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FIGURE 31 Medications and substances that may increase blood pressure.
FIGURE 32 Diagnostic work-up for patients with a suspected hypertension emergency. eGFR, estimated glomerular filtration rate; LDH, lactate dehydrogenase.
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FIGURE 34 White-coat and masked hypertension. CV, cardiovascular; HMOD, hypertension-mediated organ damage.
FIGURE 33 Hypertensive emergencies requiring immediate blood pressure lowering with intravenous drug therapy. MAP, mean arterial pressure.
Williams et al.
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FIGURE 35 Hypertension in pregnancy. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers.
FIGURE 36 Hypertension in diabetes. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; RAS, renin-angiotensin
system.
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FIGURE 37 Hypertension in chronic kidney disease. CCB, calcium channel blockers; CKD, chronic kidney disease; RAS, renin–angiotensin system.
FIGURE 38 Hypertension in coronary artery disease. CAD, coronary artery disease; CCB, calcium channel blockers.
FIGURE 39 Hypertension in left ventricular hypertrophy and heart failure. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; CCB, calcium channel
blockers; LVH, left ventricular hypertrophy; RAS, renin–angiotensin system.
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FIGURE 40 Hypertension and cerebrovascular diseases. CCB, calcium channel blocker; RAS, renin–angiotensin system; TIA, transient ischaemic attack.
FIGURE 41 Hypertension and atrial fibrillation. AF, atrial fibrillation; CCB, calcium channel blocker.
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FIGURE 42 Hypertension in perioperative diseases. CV, cardiovascular; HMOD, hypertension-mediated organ damage.
FIGURE 43 Interventions that may improve drug adherence in hypertension.
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2308 www.jhypertension.com Volume 36  Number 12  December 2018
 Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
publications cited below. Additional figures can also be
found in the printed versions of the guidelines. The grading
scale can be found as supplementary material (Supplemen-
tary Figure 1, http://links.lww.com/HJH/B29).
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